Protect Pharmaceutical IP Go back »
2023-06-15 | All chapters
During China’s drug procurement process, patent infringement of originator drugs still exists. The process of stopping patent infringement involves multiple government agencies which lack coordination.
Therefore, companies facing infringement have to go through a lengthy and difficult process when trying to defend their rights. This could lead to serious damage of the legitimate rights of multinational innovator drug companies, and subsequently lower their investment confidence in China.
The European Chamber Pharmaceutical Working Group has been advocating on this issue since 2020 calling for coordinated measures of IP protection during China’s drug procurement process.
On 30th December 2022, the NHSA and the CNIPA jointly issued a new measure, introducing a coordinated IP protection framework for the drug procurement process, which allows drug procurement agencies to remove, exclude or cancel the bidding eligibility of infringing products.
Read the story in full in English and in Chinese.
Learn more about the Pharmaceutical Working Group.